ORAI1 and pulmonary arterial hypertension: BrdU assay showed that the inhibition of Orai1 reduced PAH-hPEC proliferation by 30% (Figure 5D) as well as PAH-hPEC migration by 20% compared with siControl condition (Figure 5E), without affecting in vitro PAH-hPEC angiogenesis capacity (Supplemental Figure 6A).